BENDROFLAZIDE TABLETS 2.5MG
BENDROFLAZIDE TABLETS 2.5MG
What it does
Bendroflazide is a medication commonly used to help lower blood pressure and reduce fluid retention in the body.
Commonly used for: high blood pressure (hypertension), fluid retention (oedema)
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: Food and Drugs Authority · fetched 2026-04-18 08:33:02 · updated 2026-10-20 04:00:12
About this medicine
Bendroflazide is a medication commonly used to help lower blood pressure and reduce fluid retention in the body.
What it treats
- high blood pressure (hypertension)
- fluid retention (oedema)
How it works
Bendroflazide works by helping your kidneys remove excess salt and water from your body, which lowers blood pressure and reduces swelling.
Who it's for
This medication is for adults who need help managing high blood pressure or fluid build-up.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: bendroflazide
Bendroflumethiazide is a thiazide diuretic used primarily in the management of hypertension and edema associated with congestive heart failure, liver cirrhosis, and nephrotic syndrome. It promotes the excretion of sodium and water, thus reducing blood volume and lowering blood pressure.
Indications
- Hypertension
- Edema associated with congestive heart failure
- Edema due to liver cirrhosis
- Nephrotic syndrome
Dosage
Children: Refer to BNF for Children for specific dosing guidelines.
Adults: Refer to BNF for specific dosing guidelines.
Mechanism of action
Bendroflumethiazide acts mainly on the distal convoluted tubule in the kidneys, inhibiting the sodium-chloride symporter. This action leads to increased excretion of sodium and chloride ions, which results in diuresis. The reduction in blood volume subsequently lowers blood pressure by decreasing cardiac output and peripheral resistance.
Pharmacodynamics
The pharmacodynamic effects of bendroflumethiazide include diuresis, leading to a reduction in extracellular fluid volume. This effect helps lower systemic vascular resistance and blood pressure. Additionally, thiazide diuretics like bendroflumethiazide can cause mild metabolic changes, such as increased serum glucose and uric acid levels, which may influence the management of patients with comorbid conditions.
Pharmacokinetics
Bendroflumethiazide is well-absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1-2 hours after oral administration. It has a half-life of approximately 6-15 hours, with about 80% of the drug being excreted unchanged in the urine. Renal function can significantly affect the elimination of bendroflumethiazide, necessitating dose adjustments in patients with impaired renal function.
Contra-indications
- Anuria
- Severe renal impairment
- Hypersensitivity to bendroflumethiazide or other thiazide diuretics
- Electrolyte imbalance, particularly hypokalemia
- Severe liver disease
Adverse effects
- Hypokalemia
- Hyponatremia
- Hyperuricemia
- Gout
- Dizziness
- Headache
- Nausea
- Vomiting
- Rash
- Photosensitivity
- Pancreatitis
Interactions
- NSAIDs may reduce the diuretic effect
- Corticosteroids may increase the risk of hypokalemia
- Lithium levels may be increased leading to toxicity
- Antidiabetic agents may have reduced efficacy
- Digoxin toxicity risk may increase with hypokalemia
Precautions
- Monitor renal function regularly
- Check electrolyte levels periodically
- Caution in patients with diabetes mellitus
- Use with caution in elderly patients or those with hepatic impairment
- Assess for signs of dehydration
Pregnancy
Bendroflazide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Generally avoided in the first trimester.
Breast-feeding
Bendroflazide is excreted in breast milk; caution is advised when used during breastfeeding.
Storage
Store in a cool, dry place away from direct sunlight. Keep out of the reach of children.
Formulations
- Tablets: 2.5 mg, 5 mg
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.